LAVAL, QC, May 9, 2013 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS
Health" or the "Company") today announced that Roberto Bellini,
President and Chief Executive Officer, will present at the second
annual Bloom Burton & Co. Healthcare Investor Conference. The
presentation will take place at 4:00 pm Eastern Time on Wednesday, May
22, 2013. The conference is being held at the Toronto Board of Trade in
Mr. Bellini will provide a corporate update, including information about
the Phase III Confirmatory Study for KIACTA™, BELLUS Health's drug
candidate for the treatment of AA amyloidosis.
The Bloom Burton & Co. Healthcare Investor Conference brings together
U.S., Canadian and international investors who are interested in the
latest developments in the Canadian healthcare sector. Attendees will
have an opportunity to obtain corporate updates from the premier
Canadian publicly traded and private companies through presentations
and private meetings.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a development-focused healthcare company concentrating
on products that provide innovative health solutions and address
critical unmet medical needs. The Company's lead program is KIACTA™, a
novel drug candidate currently in a Phase III Confirmatory Study for
the treatment of AA amyloidosis, an orphan indication resulting in
renal dysfunction that often rapidly leads to dialysis and death.
KIACTA™ is partnered with global private equity firm Auven Therapeutics
(previously Celtic Therapeutics). AA amyloidosis affects approximately
35,000 to 50,000 individuals in the United States, Europe and Japan.
SOURCE: BELLUS Health Inc.
For further information:
416-815-0700 ext. 225 | email@example.com